The Business Research Company’s report on the Mantle Cell Lymphoma Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the mantle cell lymphoma therapeutics market’s growth in recent years?
The rise in the prevalence of mantle cell lymphoma is expected to propel the growth of the mantle cell lymphoma therapeutics market going forward. Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), a cancer affecting the lymphatic system. Mantle Cell Lymphoma therapeutics help reduce the disease’s prevalence by treating and managing the condition and improving patient outcomes, prolonged survival, and reduced disease burden. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library operated by the United States Federal Government, the annual incidence of mantle cell lymphoma is one case per 200,000 people, contributing to 5% of all non-Hodgkins lymphomas. Therefore, the rise in the prevalence of mantle cell lymphoma is driving the growth of the mantle cell lymphoma therapeutics market.
Access Your Free Sample of the Global Mantle Cell Lymphoma Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10813&type=smp
How does the future projection of the mantle cell lymphoma therapeutics market size compare to its historical growth?
The mantle cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from$2.42 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to advances in research, clinical trial success, improved diagnostic tools, treatment access expansion, collaborative research initiatives
The mantle cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to “$3.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to targeted therapies advancements, immunotherapy innovations, personalized medicine trends, global market expansion, increasing incidence rates. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker development, targeted therapies for specific pathways, combination therapies, integration of artificial intelligence (AI).
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10813&type=smp
Which key players are shaping the future of the mantle cell lymphoma therapeutics market?
Major companies operating in the mantle cell lymphoma therapeutics market include AstraZeneca plc, Celgene Corporation, Johnson & Johnson Consumer Inc., Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Massive Bio Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astex Pharmaceuticals Inc., Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Exelixis Inc., Hutchison China MediTech Limited, Incyte Corporation, Ionis Pharmaceuticals Inc.
What trends will propel the growth and evolution of the mantle cell lymphoma therapeutics market?
The development of targeted therapy drugs is a key trend gaining popularity in the mantle cell lymphoma therapeutics market. Major companies operating in the mantle cell lymphoma therapeutics market are developing new drugs for targeted therapy to sustain their position in the market. For instance, in March 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Calquence (acalabrutinib) from National Medical Products Administration (NMPA) to market the drug in China for adult patients who have mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a selective Bruton’s tyrosine kinase (BTK) inhibitor, and it is used to offer a tolerable and effective new treatment option to help control mantle cell lymphoma.
Which regions are expected to become dominant players in the mantle cell lymphoma therapeutics market?
North America was the largest region in the global mantle cell lymphoma therapeutics market in 2024. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
What are the emerging key segments in the mantle cell lymphoma therapeutics market, and how are they evolving?
The mantle cell lymphoma therapeutics market covered in this report is segmented –
1) By Type: Combination Therapy, Monotherapy
2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms
3) By Route of Administration: Oral, Parenteral
4) By Application: Hospital, Research Institute, Other Applications
Subsegments:
1) By Combination Therapy: Chemotherapy Combinations, Targeted Therapy Combinations, Immunotherapy Combinations
2) By Monotherapy: Single-Agent Chemotherapy, Targeted Therapy Monotherapy, Immunotherapy Monotherapy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10813
What defines the structure and scope of the mantle cell lymphoma therapeutics market?
Mantle cell lymphoma therapeutics refers to treatment approaches and strategies used to manage mantle cell lymphoma (MCL); a type of non-Hodgkin lymphoma characterized by abnormal B-cell growth in the lymphatic system. These treatments use focused strategies like BTK and BCL2 inhibitors, which have long-lasting therapeutic effects.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
